Mobile

Study to allow access to imatinib for patients who are on imatinib treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002540-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate long term safety data (SAEs and AEs).

Critère d'inclusion

  • Male and female patients who are currently enrolled in a Novartis-sponsored, Oncology OGD&GMA imatinib study, are benefiting from treatment with imatinib and have fulfilled all their requirements in the parent study

Liens